| Name | Title | Contact Details |
|---|---|---|
Vinay Gidwaney |
Head of Technology | Profile |
American Specialty Health Incorporated (ASH) provides health plans, employer groups, insurance carriers and trust funds with a wide range of wellness and population health, fitness and exercise, and specialty health care management programs to improve the health of their employees or members. Our Healthyroads® program is one of the largest employee wellness and prevention programs, serving hundreds of employer groups and more than 5 million members across the country. From telephone and online health coaching to wellness incentive programs to worksite health challenges, we offer it all under one roof. Our fitness and exercise services, including Silver&Fit® for Medicare Advantage members and Active&Fit® for commercial members, provide no-cost, low-cost, discount, or reimbursement fitness club/exercise center membership programs; walking, home exercise, and reward programs; as well as Internet-based exercise tools. And our specialty health provider programs for health plans contract with more than 30,000 specialty health care practitioners. Headquartered in Carmel, IN, with offices in San Diego, CA, Dallas, TX and Columbia, S.C., ASH has more than 1,200 employees and administers programs for more than 31 million members nationwide. Other products offered through ASH and its subsidiaries include ExerciseRewards™, FitnessCoach™, and others.
Care New England Health System (CNE) is a Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Westphalia Retirement Ctr is a Westphalia, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Burke Williams is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.